Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net income (loss)	$ (513,965)	$ 936,335
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	217,086	230,342
Amortization of operating lease right-of-use assets	22,887	16,358
Provision for bad debts	40,041	0
Accretion of discount on note receivable	0	(1,048,402)
Share-based compensation	624,064	44,928
Interest income accrued on note receivable	(24,435)	(155,198)
Changes in assets and liabilities:
Accounts receivable	(164,157)	(7,901)
Prepaid expenses and other current assets	54,641	(196,251)
Accounts payable	(388,271)	(284,122)
Accrued expenses	63,550	93,738
Contract liabilities	12,219	243,772
Operating lease obligations	(22,674)	(16,335)
Net cash used inoperating activities	(79,014)	(142,736)
Cash flows from investing activities
Purchase of property and equipment	(2,467)	(6,572)
Issuance of notes receivable	(75,000)	(748,500)
Net cash used in investing activities	(77,467)	(755,072)
Cash flows from financing activities
Repurchase of common stock	0	(3,996)
Proceeds from option exercises	2,212	0
Net cash provided by (used in) financing activities	2,212	(3,996)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents	18,688	(61,097)
Net change in cash and cash equivalents	(135,581)	(962,901)
Cash and cash equivalents, beginning of period	1,284,965	2,052,421
Cash and cash equivalents, end of period	1,149,384	1,089,520
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Income taxes	6,865	9,416
Interest	0	0
SUPPLEMENTAL DISCLOSURES OF NON-CASH ITEMS
Increase in note receivable for reimbursable expenses	0	50,000
Increase in note receivable for discount	0	847,193
Issuance of common shares in settlement of accrued common stock bonus	193,246	84,576
Operating lease liabilities from obtaining lease right-of-use assets	$ 0	$ 130,506